Fibroblast Growth Factors and Their Receptors in Major Depressive Disorder: A Scoping Review of Translational Research.
- 1Department of Adult Psychiatry, Medical University of Lodz, 91-229 Lodz, Poland.
- 2International Doctoral School, Medical University of Lodz, 90-647 Lodz, Poland.
Abstract
Major depressive disorder (MDD) is a complex psychiatric condition whose pathophysiology extends beyond the classic monoamine hypothesis, involving impaired neuroplasticity, neuroinflammation, HPA axis dysregulation, and altered neurotrophic signaling. The fibroblast growth factor (FGF) system, comprising ligands and their receptors (FGFRs), has emerged as a key candidate regulator of these processes. This scoping review qualitatively synthesizes current clinical, postmortem, and preclinical evidence on the role of the FGF system in MDD and antidepressant response. A structured literature search according to PRISMA-ScR was conducted in PubMed/MEDLINE and Scopus without date restrictions. Eligible studies included human (clinical, postmortem), preclinical, and translational data investigating FGF/FGFR expression, signaling, manipulation, or peripheral biomarker associations in the context of depression or antidepressant action. Of 287 unique records screened, 68 met the inclusion criteria; together with 11 studies identified through backward citation searching, 79 studies were included in the qualitative synthesis. This synthesis outlines a bidirectional role for the fibroblast growth factor (FGF) system in major depressive disorder (MDD). Rather than acting as a uniform pathway, different FGF ligands exert opposing regulatory effects on mood, neuroplasticity, and stress responses. FGF-2 exerts protective and neurotrophic effects, while factors like FGF-9 act as endogenous prodepressants. Although circulating biomarkers show heterogeneity, central FGF/FGFR signaling represents a promising target for novel therapeutic strategies and personalized treatment approaches in MDD.
Related
- Frequency and correlates of inaccurate psychiatric diagnoses in 401 adults hospitalized for major depressive disorder: a comparison of clinical versus research interview-based diagnoses
- Artificial intelligence in eating disorder research: a scoping review with bibliometric analysis of trends, methodologies, and translational readiness (2016-2025).
- Targeting the NLRP3 inflammasome in rheumatoid arthritis fibroblast-like synoviocytes: pathogenic mechanisms, therapeutic strategies, and translational perspectives
- Pupil size-resting state network coupling in major depressive disorder: a longitudinal iTBS study
- Biologically informed network-regularized sparse consensus clustering (BioNet-SPACC) identifies a continuous plasma proteomic axis in major depressive disorder
BibTeX
@article{ryznar2026fibroblast,
title = {{Fibroblast Growth Factors and Their Receptors in Major Depressive Disorder: A Scoping Review of Translational Research.}},
author = {Gracja Ryznar and Piotr Gałecki and Katarzyna Bliźniewska-Kowalska},
journal = {International journal of molecular sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198464},
url = {https://europepmc.org/article/MED/42883713},
note = {CC BY},
}
RIS
TY - JOUR
TI - Fibroblast Growth Factors and Their Receptors in Major Depressive Disorder: A Scoping Review of Translational Research.
AU - Gracja Ryznar
AU - Piotr Gałecki
AU - Katarzyna Bliźniewska-Kowalska
PY - 2026
DA - 2026/09/23
JO - International journal of molecular sciences
DO - 10.3390/ijms27198464
UR - https://europepmc.org/article/MED/42883713
AB - Major depressive disorder (MDD) is a complex psychiatric condition whose pathophysiology extends beyond the classic monoamine hypothesis, involving impaired neuroplasticity, neuroinflammation, HPA axis dysregulation, and altered neurotrophic signaling. The fibroblast growth factor (FGF) system, comprising ligands and their receptors (FGFRs), has emerged as a key candidate regulator of these processes. This scoping review qualitatively synthesizes current clinical, postmortem, and preclinical evidence on the role of the FGF system in MDD and antidepressant response. A structured literature search according to PRISMA-ScR was conducted in PubMed/MEDLINE and Scopus without date restrictions. Eligible studies included human (clinical, postmortem), preclinical, and translational data investigating FGF/FGFR expression, signaling, manipulation, or peripheral biomarker associations in the context of depression or antidepressant action. Of 287 unique records screened, 68 met the inclusion criteria; together with 11 studies identified through backward citation searching, 79 studies were included in the qualitative synthesis. This synthesis outlines a bidirectional role for the fibroblast growth factor (FGF) system in major depressive disorder (MDD). Rather than acting as a uniform pathway, different FGF ligands exert opposing regulatory effects on mood, neuroplasticity, and stress responses. FGF-2 exerts protective and neurotrophic effects, while factors like FGF-9 act as endogenous prodepressants. Although circulating biomarkers show heterogeneity, central FGF/FGFR signaling represents a promising target for novel therapeutic strategies and personalized treatment approaches in MDD.
SN - 1422-0067
ER -